Aquatic Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Aquatic Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-24,061	Closed	-$596K	–	1341
2026 Q1	$596K	Buy	+24,061	New	+$573K	0.02%	703
2025 Q2	–	Sell	-70,066	Closed	-$1.7M	–	1284
2025 Q1	$1.7M	Buy	70,066 +40,805	+139%	+$919K	0.04%	455
2024 Q4	$611K	Sell	29,261 -18,008	-38%	-$387K	0.02%	673
2024 Q3	$940K	Buy	47,269 +32,569	+222%	+$604K	0.02%	513
2024 Q2	$228K	Buy	14,700 +5,200	+55%	+$81K	0.01%	722
2024 Q1	$151K	Buy	+9,500	New	+$143K	﹤0.01%	830
2023 Q4	–	Sell	-31,700	Closed	-$371K	–	1375
2023 Q3	$371K	Buy	+31,700	New	+$424K	0.02%	544
2023 Q2	–	Sell	-103,400	Closed	-$1.71M	–	1408
2023 Q1	$1.71M	Buy	+103,400	New	+$1.71M	0.11%	211
2022 Q4	–	Sell	-300	Closed	-$4K	–	1443
2022 Q3	$4K	Sell	300 -7,500	-96%	-$88.9K	﹤0.01%	1096
2022 Q2	$55K	Buy	+7,800	New	+$57.2K	0.02%	623

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aquatic Capital Management's CPRX Position: Q2 2026 in Review

Aquatic Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 24,061 shares — an estimated $596K sold.

Aquatic Capital Management first reported a position in CPRX in Q2 2022 and held it in 10 quarters. The position peaked at $1.71M in Q1 2023. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Aquatic Capital Management reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Aquatic Capital Management sold 24,061 Catalyst Pharmaceutical shares in Q2 2026, an estimated $596K.
Aquatic Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2022 and held it in 10 quarters.
Aquatic Capital Management's Catalyst Pharmaceutical position peaked at $1.71M in Q1 2023.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.